Investment
Features
FeesSafety
Academy
More
Pluang+

Accsys expects higher adjusted EBITDA despite 6% revenue drop amid cautious market conditions.

Company Fundamentals
21 Sep 2026
Proactive Investors
View Source
Neutral
Accsys expects higher adjusted EBITDA despite 6% revenue drop amid cautious market conditions.

Accsys Technologies Plc forecasts full-year adjusted EBITDA between €21 million and €23 million, surpassing last year's results despite a 6% revenue decline to €56.9 million in the first five months. Sales volumes dropped 11%, impacted by distributor destocking, inflation, higher interest rates, and geopolitical tensions, particularly in North America. The company sees signs of recovery with stabilizing inventory levels and stronger activity in September. Accsys remains on track with its FOCUS strategy, targeting improved capacity, cost management, innovation, and market share growth, with interim results due November 24.

Accsys Technologies forecasts adjusted EBITDA between €21 million and €23 million after a 6% revenue fall. For readers following Basic Materials, here is Pluang's market snapshot as of Sep 21, 2026 14:21 WIB: 18 of 34 US stocks rose and 15 fell. Notable movers include GFI at USD 41.95 with a -1.27% change, ALB at USD 112.17 with +1.14%, and MT at USD 73.23 with +0.97%.

More News

Prismo Metals maps a large alteration system at Silver King, indicating a deep porphyry copper target.

Prismo Metals maps a large alteration system at Silver King, indicating a deep porphyry copper target.

Prismo Metals completed its 2026 surface reconnaissance at the Silver King project in Arizona, revealing an alteration system over 2 km wide with classic porphyry copper zoning. The findings include expanded potassic alteration, phyllic overprinting,...

Market News
Bullish
4 hours ago
Coiled Therapeutics enrolls patients for new softgel cancer drug trial to improve absorption and dosing.

Coiled Therapeutics enrolls patients for new softgel cancer drug trial to improve absorption and dosing.

Coiled Therapeutics has enrolled six patients into two dosing groups testing a reformulated version of its cancer drug AO-252, designed to better cross the brain and block the cancer-driving protein TACC3. The new lipid-based softgel aims to provide ...

Market News
Bullish
4 hours ago
Iofina targets record iodine output in 2026 as profits surge on higher production and margins

Iofina targets record iodine output in 2026 as profits surge on higher production and margins

Iofina PLC expects to produce a record volume of iodine in 2026, with output forecasted between 460 and 485 metric tonnes in the second half of the year. The company reported a sharp rise in profitability for the first half, with adjusted core earnin...

Company Fundamentals
Bullish
4 hours ago
Chevron turns Middle East supply shocks into strong earnings with limited regional risk

Chevron turns Middle East supply shocks into strong earnings with limited regional risk

Chevron Corporation is capitalizing on Middle East supply disruptions to deliver strong earnings and cash flow, benefiting from high oil prices and operational efficiencies. The company’s limited direct exposure to the region has minimized physical r...

Market News
Bullish
4 hours ago
XRP rebounds above $1.40 as whales buy $2.2B tokens, eyeing $1.50 resistance for potential breakout.

XRP rebounds above $1.40 as whales buy $2.2B tokens, eyeing $1.50 resistance for potential breakout.

XRP has bounced back above $1.40 following a recovery from lows around $1.24–$1.26. Major holders accumulated about 1.54 billion XRP tokens worth approximately $2.2 billion in just 96 hours, signaling strong whale interest. Additionally, around 1.6 b...

Technical Signals
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App